Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03597295 · BASELINE

Baseline characteristics

A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202) · Source last updated 2025-08-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      94
    units
    Participants
groups
  1. description
    Participants received retifanlimab 500 milligrams (mg) intravenously every 4 weeks (Q4W).
    id
    BG000
    title
    Retifanlimab 500 mg
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          11.44
          value
          62.1
    denom Units Selected
    Participants
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    Years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          61
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          33
        title
        Male
    denom Units Selected
    Participants
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          4
        title
        Hispanic or Latino
      2. measurements
        1. group Id
          BG000
          value
          49
        title
        Not Hispanic or Latino
      3. measurements
        1. group Id
          BG000
          value
          33
        title
        Not Reported
      4. measurements
        1. group Id
          BG000
          value
          4
        title
        Unknown
      5. measurements
        1. group Id
          BG000
          value
          4
        title
        Missing
    denom Units Selected
    Participants
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Race/Ethnicity, Customized
    unit Of Measure
    Participants
  4. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          72
        title
        White/Caucasian
      2. measurements
        1. group Id
          BG000
          value
          1
        title
        Black/African-American
      3. measurements
        1. group Id
          BG000
          value
          4
        title
        Captured as "Other"
      4. measurements
        1. group Id
          BG000
          value
          6
        title
        Missing
      5. measurements
        1. group Id
          BG000
          value
          11
        title
        Not Reported
    denom Units Selected
    Participants
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Race/Ethnicity, Customized
    unit Of Measure
    Participants
population Description
The Full Analysis Set (FAS) included all participants enrolled in the study who received at least 1 dose of study drug.
type Units Analyzed
94
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      94
    units
    Participants
groups
  1. description
    Participants received retifanlimab 500 milligrams (mg) intravenously every 4 weeks (Q4W).
    id
    BG000
    title
    Retifanlimab 500 mg
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          11.44
          value
          62.1
    denom Units Selected
    Participants
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    Years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          61
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          33
        title
        Male
    denom Units Selected
    Participants
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          4
        title
        Hispanic or Latino
      2. measurements
        1. group Id
          BG000
          value
          49
        title
        Not Hispanic or Latino
      3. measurements
        1. group Id
          BG000
          value
          33
        title
        Not Reported
      4. measurements
        1. group Id
          BG000
          value
          4
        title
        Unknown
      5. measurements
        1. group Id
          BG000
          value
          4
        title
        Missing
    denom Units Selected
    Participants
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Race/Ethnicity, Customized
    unit Of Measure
    Participants
  4. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          72
        title
        White/Caucasian
      2. measurements
        1. group Id
          BG000
          value
          1
        title
        Black/African-American
      3. measurements
        1. group Id
          BG000
          value
          4
        title
        Captured as "Other"
      4. measurements
        1. group Id
          BG000
          value
          6
        title
        Missing
      5. measurements
        1. group Id
          BG000
          value
          11
        title
        Not Reported
    denom Units Selected
    Participants
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Race/Ethnicity, Customized
    unit Of Measure
    Participants
population Description
The Full Analysis Set (FAS) included all participants enrolled in the study who received at least 1 dose of study drug.
type Units Analyzed
94

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice